Analysts' Recent Ratings Changes for Intra-Cellular Therapies (ITCI)

Several analysts have recently updated their ratings and price targets for Intra-Cellular Therapies (NASDAQ: ITCI): 4/24/2024 – Intra-Cellular Therapies had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock. 4/23/2024 – Intra-Cellular Therapies had its price target raised by analysts at Canaccord Genuity Group Inc. […]

Related Keywords

Canada ,United States ,America ,Michael Halstead ,Robertw Baird ,Quantum Private Wealth ,Cellular Therapies Inc ,Royal Bank ,Cantor Fitzgerald ,America Co ,Phocas Financial Corp ,Healthcare Of Ontario Pension Plan Trust Fund ,Securities Exchange Commission ,Canaccord Genuity Group Inc ,Goldman Sachs Group Inc ,Needham Company ,Cellular Therapies Inc Daily ,Intra Cellular Therapies ,Canaccord Genuity Group ,Goldman Sachs Group ,Cellular Therapies Stock Down ,Cellular Therapies ,Get Free Report ,Exchange Commission ,Private Wealth ,Minvest Partners ,Ontario Pension Plan Trust Fund ,Intra Cellular Therapies Inc Daily ,Intra Cellular Therapies Inc ,Nasdaq Itci ,Bitci ,